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Abstract
The molecular origin of X-linked hyper IgM syndrome has
recently been identified as a defect in the ligand of CD40,
gp39, a protein expressed on the surface of activated T cells.
The availability of detailed pedigrees for three families with
affected males allowed assessment of the random or nonran-
dom nature of the inactivation of the defective X chromo-
some as well as a determination of the origin of the mutation.
X chromosome inactivation was studied because of the rele-
vance to the ability to detect carriers of HIGM1 and the
potential for phenotypic effect in the carriers. Using immu-
nostaining, PCR, and DNA sequencing, we found that the
defective gene for gp39 is not selectively inactivated. Even
in the presence of extremely skewed inactivation, normal
levels of serum Ig were found. In carriers in which the
defective gene is predominantly expressed, staining alone
revealed the carrier status reliably while cloning and se-
quencing of the cDNA was necessary when the normal gene
was predominantly expressed. Unlike some other X-linked
defects where extreme Lyonization may lead to disease, a
small population of cells expressing the wild-type gp39 is
sufficient to maintain normal humoral immtuniy and pre-
vent the clinical symptoms of X-HIM. (J. Clin. Invest. 1994.
94:616-622.) Key words: Lyonization * X-linked hyper IgM
syndrome - carrier detection * CD40 gp39
Introduction
X-linked hyper IgM syndrome (X-HIM)1 is a primary immuno-
deficiency disorder characterized by hypogammaglobulinemia
and recurrent bacterial infections. Affected males have normal
levels of circulating T and B cells, normal to elevated levels of
serum IgM, low levels of IgG, and nondetectable levels of IgE
or IgA. As a result of the impaired immune response, affected
males are susceptible to bacterial and opportunistic infections,
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1. Abbreviations used in this paper: X-HIM, X-linked hyper IgM syn-
drome; XLA, X-linked agammaglobulinemia.
generally beginning at the end of the first or early in the second
year of life. The clinical manifestations ofX-HIM include recur-
rent upper respiratory tract infections, pneumonia, diarrhea, oti-
tis media, occasional lymphoid hyperplasia, and frequent neu-
tropenia. In addition, it appears that affected males, as a group,
are unusually susceptible to Pneumocystis carinii. Though intra-
venous immunoglobulin infusions are effective, X-HIM patients
may succumb to opportunistic infection early in life or to
lymphomas or other malignancies during childhood or early
adulthood (1).
The molecular basis of X-HIM has recently been shown to
result from defects in the T cell surface protein gp39. Studies
designed to elucidate the role of lymphocyte cell surface pro-
teins in T cell-B cell interactions have previously led to the
identification and characterization of the gp39/CD40 ligand re-
ceptor pair as important in B cell proliferation and antibody
isotype switching (2-4). Gp39 (CD40L, Trap) is a type II mem-
brane glycoprotein expressed on the surface of T cells 6-8 h
after activation (5-8). CD40 is a type I membrane glycoprotein
(9) constitutively expressed by B cells (2), monocytes (10),
follicular dendritic cells, basal and thymic epithelial cells (11,
12), and some tumor-derived cell lines (13). Stimulation of the
CD40 receptor with anti-CD40 monoclonal antibodies (mAbs)
or recombinant gp39 in conjunction with IL-4 or IL-10 results
in B cell proliferation and the production of IgE or IgA, IgG
and IgM immunoglobulin isotypes, respectively (3, 14-18) (S.
Nonoyama, unpublished observations). Stimulation of CD40
on monocytes and thymic epithelial cells modulates cytokine
secretion by these two cell types (10).
Two independent approaches led to the determination that
defects in the gp39 gene are the molecular basis for X-HIM. In
the first approach, the role of the gp39/CD40 interaction was
examined in several primary immunodeficiency disorders, in-
cluding common variable immunodeficiency (CVI), X-linked
agammaglobulinemia (XLA) and X-HIM. These studies demon-
strated that peripheral blood T cells from X-HIM patients fail
to express detectable levels of functional gp39 protein following
in vitro activation, yet these cells express levels of mRNA en-
coding gp39 within the normal range. Sequencing of gp39
cDNAs obtained from X-HIM patients showed that they con-
tained point mutations. It was subsequently shown that these
point mutations abolished the ability of gp39 to bind to CD40
and drive B cell proliferation and isotype switching (15). In a
different approach, the gene encoding gp39 was found to be
localized to the same area of the X chromosome as the gene
responsible for X-HIM. This initiated an examination of the
gp39 protein levels expressed by activated T cells from patients
with X-HIM. The observation that the T cells from affected
patients expressed no functional gp39 led to DNA sequencing
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experiments and the demonstration of mutations in the gp39
gene in individuals with X-HIM (19-22).
Knowledge of the genetic basis of HIGM I allows examina-
tion of the possibility of nonrandom X chromosome inactivation
in female carriers and sets the stage for the development of
methodologies for the detection of female carriers and prenatal
diagnosis. Here we describe the detailed pedigree analysis of
three families with affected males, which allowed us to identify
five female carriers of HIGM 1. We investigated the inactivation
of the defective X chromosome in these female carriers by
immunofluorescence staining, to identify the fraction of in vitro
activated T cells expressing functional gp39, and by DNA se-
quencing of multiple independent cDNA clones obtained
by PCR.
Methods
Patients and their families. C.D., the only affected male in Family 1,
is a 15-yr-old boy with a history of frequent bacterial infections since
infancy, moderately elevated IgM, low IgG, and absent IgA. His half-
sister, mother, and two maternal uncles are healthy and alive. The four
brothers of his maternal grandmother were healthy through adulthood;
two are still alive.
J.W., the second son of a healthy mother, developed P. carinii during
infancy and subsequently had recurrent bacterial infections. His serum
IgM is persistently elevated, IgG is low, and IgA is absent. At 12 years
of age, he developed immune complex disease after a viral infection,
and developed severe renal disease, resulting in therapy-resistant hyper-
tension. He died at the age of 25, of cerebral hemorrhage. His older
brother died at 5 mos old of P. carinii; serum IgM was elevated. The
maternal grandparents were healthy and handled infections well.
Five of six brothers in Family 3 are affected with X-HIM. One boy
died during infancy of P. carinii. The other four brothers have recurrent
bacterial infections; two have neutropenia and all show elevated serum
IgM, low IgG, and absent or low IgA. The mother and five maternal
aunts are asymptomatic. Together, the five maternal aunts have 16 boys
and 11 girls, all of whom are healthy. The only maternal uncle and the
maternal grandmother are healthy.
Isolation and characterization ofgp39 cDNAs. PBMCs were isolated
from heparinized whole blood by centrifugation over lymphocyte sepa-
ration medium (Organon Teknika Corp., Durham, NC). Cells were
washed twice in RPMI 1640 and cultured under standard conditions
(370C, 6% C02) in RPMI 1640 containing 10% fetal calf serum
(HyClone Laboratories), 100 U/ml penicillin and 100 Mg/ml streptomy-
cin. Cells were activated in the presence of PMA (10 ng/ml) and iono-
mycin (1 yg/ml) for 8 h. 107 cells were pelleted and immediately lysed
in 0.5 ml lysis buffer (4 M guanidinium thiocyanate, 25 mM sodium
citrate pH 7, 1% Sarkosyl and 100 mM 2-mercaptoethanol). To the
lysate was added 50 p1] 2 M sodium acetate pH 4, 0.5 ml water-saturated
phenol and 200 pl chloroform. The mixture was vortexed and centri-
fuged and the aqueous layer transferred to a new tube. RNA was precipi-
tated by the addition of an equal volume of isopropanol followed by
incubation on ice for 1 h. After centrifugation, pellets were washed one
time with 70% ethanol, dried and resuspended in 30 p1 RNAase-free
water. Concentration of RNA was measured by UV absorbance. 5 pg
total RNA was incubated with 2.5 pig oligo(dT) 15 in 20 M1 at 700C for
5 min. On ice, remaining reaction components were added to a final
volume of 50 M1 (50 mM Tris [pH 8.8 at room temperature] 50 mM
KCI, 6 mM MgCI2, 0.25 mM dNTP, 10 mM dithiothreitol, 8 mM
sodium pyrophosphate, 40 U RNAsin RNAase inhibitor [Promega, Mad-
ison, WI], 108 U avian myeloblastosis virus reverse transcriptase (Life
Sciences Inc., St. Petersburg, FL). Reactions were incubated at 420C
for 3.5 h, then heated to 100°C for 10 min, and placed on ice. PCRs
were performed using Pfu polymerase (Stratagene, La Jolla, CA) or
Taq polymerase (Perkin-Elmer Corp., Norwalk, CT) according to the
manufacturers recommendations using oligonucleotide primers at the 5'
and 3' ends of the coding region as previously described (6). As a
template, 0.1 or 1 M1 of the cDNA reaction mixture was used. PCR
products from affected males were sequenced directly following asym-
metric PCR as described previously (6). PCR products obtained from
females and unaffected males were cloned into a CDM8 vector and
sequenced by dideoxy sequencing using Sequenase (United States Bio-
chemical Corp., Cleveland, OH). PCR products from members of family
3 or a normal control were used as templates in PCR reactions using
primers flanking the deleted region. Primers were 5'-ATAATGTTA-
AACAAAGCGG-3' and 5'-GGAC=TFFAGGCAGAGGCTGGC-3'.
PCR products were separated on a standard 2% agarose gel. For all
PCRs performed, control reactions were included to which no template
DNA had been added to verify the absence of contaminating DNA.
Two-color cell staining. PBMCs were washed twice in RPMI 1640
and resuspended to a final density of 1.5 x 107 cells/ml. Monoclonal
antibodies IF5 (anti-CD20) and Gl 0-I (anti-CD8) were added to a final
concentration of 10 pg/ml and incubated on ice for 45 min. Rabbit
complement (Pel-Freeze Biologicals, Rogers, AR) was added and the
mixture incubated at 370C for 40 min. Cells were washed twice in
Iscoves medium and resuspended at a density of 2 x 107 cells/ml. An
equal volume of 0.5 mM Leu-Leu-OMe (Sigma Chemical Co., St. Louis,
MO) was added and cells incubated at room temperature for 15 minutes
to remove monocytes and remaining NK cells and cytotoxic T lympho-
cytes (23). Cells were diluted with serum-free Iscoves medium, centri-
fuged 15 min at 1,400 rpm, and washed once more with serum-free
Iscoves. Cells were resuspended in RPMI 1640 containing 10% fetal
calf serum (Hyclone Laboratories, Logan, UT), 100 U/ml penicillin and
100 Mg/ml streptomycin and cultured overnight under standard condi-
tions. Cells were activated by the addition of PMA (10 ng/ml) and
ionomycin (1 Mg/ml). After 8 h, cells were washed once with staining
media (RPMI 1460 containing 2% fetal calf serum and 0.1% NaN3).
1-5 X 105 cells per sample were stained on ice. Antibodies used were
PE-conjugated anti-CD3 and anti-CD69 and FITC-conjugated anti-CD4
(Becton Dickinson, Mountain View, CA), PE-conjugated anti-Mac I
(Boehringer Mannheim, Indianapolis, IN), FITC-conjugated B43 (anti-
CD1 9) (24), CD40-Ig (prepared as previously described) (6), and FITC-
conjugated goat anti-human Ig (Tago, Inc., Burlingame, CA).
Results
Pedigree analysis offamilies with HIGMJ. As previously re-
ported, the index case (C.D.) of Family I (Fig. 1 A) has two
point mutations, at positions 405 and 407 of the gp39 cDNA,
which result in substitution of two amino acids and the inability
of the mutated gp39 to bind to its ligand CD40, and a silent
polymorphism at position 169 as compared with the original
gp39 sequence (6, 15). DNA sequencing of multiple indepen-
dent cDNA clones encoding gp39 from members of Family 1
indicated that both C.D.'s mother (K.H.) and sister (D.R.) are
carriers of HIGM 1 and express genes corresponding to the wild
type and the defective gp39, while the maternal grandmother
(W.H.) expresses only the wild-type gene and is not a carrier.
For K.H., 9 of 12 independent gp39 cDNA clones encoded the
wild type sequence, while for D.R., only 4 of 14 independent
gp39 cDNA clones were wild type. In both instances the defec-
tive gene carried the gp39 polymorphism at position 169. DNA
sequencing analysis of the maternal grandmother showed that
she carries two wild type gp39 genes, one with the polymor-
phism of C.D. (10 of 18 independent cDNA clones) and one
without (8 of 18 independent cDNA clones). Similar analysis
of the cDNAs encoding gp39 from the maternal grandfather
indicated that he carries a gp39 gene which contains the poly-
morphism (4 of 4 independent cDNA clones). These data sug-
gest that the mother inherited the polymorphic allele from her
father and the defect is a paternally derived de novo mutation
arising in the mother, K.H.
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Figure 1. Pedigrees of two families of HIGMI. The notation of + and
- refers to the mutations relative to the original gp39 sequence in
sequential order; The first symbol indicates the presence (+) or absence
(-) of the silent polymorphism at position 169 found in both families.
Numbers given refer to the number of clones identified with the given
sequence. (A) Family 1. The second and third symbols refer to the
presence (+) or absence (-) of the mutations at positions 405 and 407
that result in the defect in the index case CD. (B) Family 2. The second
symbol refers to the presence (+) or absence (-) of the mutation at
position 724 that results in the defect in the index case J.W.
The index case of Family 2, J.W., has a point mutation at
position 724 resulting in a single amino acid substitution, and
the same silent polymorphism at position 169 as found in C.D.
(15). J.W.'s mother, J.S., is an obligate carrier having two af-
fected male offspring (Fig. 1 B). Sequencing of gp39 cDNAs
derived from mRNA isolated from in vitro stimulated PBMCs
from J.S. demonstrated the presence of both alleles, the wild
type and mutant, and the polymorphism at position 169 was
found on the mutant allele. The low frequency of the mutant
clones suggested that her T cells predominantly express the
wild type gp39 gene (47 of 48 independent cDNA clones were
wild type). J.W.'s maternal grandfather, M.J., carries a gene
which contains the polymorphism at position 169 (7 of 7 inde-
pendent clones). This suggests that the defect in this family
is also a paternally derived de novo mutation. The maternal
grandmother was not available for analysis.
Using PCR and DNA sequencing, we have identified the
gp39 defect in a third family (Family 3, Fig. 2 A). In this family,
the mutation consists of a 63-base pair deletion that results in an
inframe deletion of 21 amino acids within the TNF homologous
extracellular domain of gp39 (Fig. 2 B). This mutation is the
404-
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Figure 2. (A) Pedigree of Family 3. Carrier status of R.C.3 is not reported
at the family's request. (B) Schematic representation of the location of
the deletion resulting in the defect in Family 3. PCR analysis of cDNA
obtained from four family members using primers at positions 313 and
612.
same defect previously reported in an unrelated case (21). The
large deletion allowed the use of a PCR-based approach for the
identification of affected males and female carriers in this fam-
ily. PCR reactions of cDNA derived from the activated PBMC
of the affected males yielded fragments significantly smaller
than those obtained for the normal control and of the size ex-
pected based on the 63-bp deletion. A similar analysis of the
mother, C.C., an obligate carrier, and one daughter, J.C., re-
vealed two gp39 DNA fragments consistent with the presence
of a wild-type and a mutant gene (Fig. 2 B). The carrier status
of the second daughter, R.C.3, is not described at the family's
request. This PCR based approach does not permit an evaluation
of which gene, wild type or defective, is preferentially ex-
pressed.
Cell surface expression of functional gp39 by activated T
cellsfromfemale carriers. The DNA sequencing data described
above indicate that T cells in which the normal X chromosome
is active are not preferentially selected in female carriers of
X-HIM. To determine if the proportion of activated T cells
618 Hollenbaugh et al.
I1
11l
IV
A Family 1
N.C.
.0 W.
E I.%m II
z
'.H.
K.H.
,
D.R.
0 1 2
Log Fluorescence
B Family 2
PI N.C.
I,,K I
E /
z
Q)
J.S.
0
o- 1I
I
I'
*j I
o 1 2 3 4
Log Fluorescence
Figure 3. Flow cytometry analysis of activated PBMC stained with CD40-
Ig to detect the proportion of cells expressing functional gp39. (A) Family
1. K.H. and D.R. are carriers of HIGM. (B) Family 2. J.S. is a carrier of
HIGM.
expressing functional gp39 mirrored the DNA sequencing data,
PBMCs isolated from female carriers were activated in vitro and
examined for the expression of functional gp39 using CD40-Ig
and flow cytometry. Both female carriers in Family 1 (K.H. and
D.R.) had only a small percentage of the PBMC expressing
functional gp39 (23 and 12%, respectively, as compared with
63% in the normal control, Fig. 3 A). The single female carrier
of Family 2 (J.S.) had numbers of cells expressing functional
gp39 that were indistinguishable from normal controls (Fig. 3
B). In Family 3, activated PBMC from the two family members
studied (C.C. and J.C.) expressed the mutant gp39 gene at an
intermediate level (data not shown).
Effect of heterozygosity on serum Ig levels. Levels of Ig in
the serum of the HIGMI female carriers were analyzed (Table
I). Values of serum IgM, IgG, IgA, or IgE for the female carriers
were all within the normal range, with the exception of slightly
elevated IgM levels for C.C. and low IgA levels seen for D.R.
As IgA deficiency is common and is not seen in the other
carriers, the low IgA levels seen for D.R. are expected to be
unrelated to her status as an HIGM1 carrier.
Detection of female carriers of HIGMJ. Because of the
random inactivation of the X chromosome in female carriers of
HIGMI, analysis of CD40-Ig binding to activated PBMCs may
provide sufficient information for a definitive diagnosis of a
carrier state. In cases where the wild-type gene is predominantly
Table 1. Serum Ig Levels (mg/dL) of Female Carriers ofHIGM
Patient IgA IgG IgM IgE
J.S. 292 1060 157 36
K.H. 124 766 254 9
D.R. 10 1520 233 14
C.C. 393 1420 373 238
J.C. 209 1350 318 26
Normal range 80-500 725-1750 40-350 0-300
expressed, it was not possible to detect the slight reduction in
staining with CD40-Ig due to the expression of defective gp39
(Fig. 3 B). In an effort to develop methods which could better
detect female carriers, we isolated subpopulations of cells and
analyzed the expression of gp39 after activation. Only 20-30%
of the total CD8' population express gp39 (data not shown).
However, greater than 90% of CD4' T cells are positive for
staining with CD40-Ig. To use this population, CD4' T cells
were isolated from normal donors and from female carriers
from Families 1, 2, and 3 by complement and Leu-Leu-OMe
depletion. These cells were then activated in vitro, stained with
CD40-Ig and either anti-CD69, a marker of activation, or anti-
CD3 mAb and analyzed by flow cytometry. Physical isolation
ofCD4' cells was necessary since CD4 expression is downregu-
lated after T cell activation. Two color immunofluorescence
studies of activated CD4+ T cells obtained from unaffected
individuals showed cells which are CD69+ and CD3+ are also
gp39+ (Fig. 4 and data not shown; 93% of CD3+ cells and 91%
of CD69+ cells are gp39+). In contrast, activated CD4+ T cells
isolated from female carriers from Families 1 and 3 showed a
significant population of cells which are gp39- and CD3+ and
gp39- and CD69+. (Of CD3+ cells, 68, 65, 51, 33% are gp39-
for K.H., D.R., C.C., and J.C., respectively; Of CD69+ cells,
66, 63, 57, 38%, are gp39-). However, for the carrier J.S., no
significant difference from the normal control could be detected
(Fig. 4; 73% of CD3+ cells and 81% of CD69+ cells are gp39+).
Piscussion
The subject of chromosomal inactivation in HIGM1 has been
controversial. Reports showing preferential inactivation of the
mutated X chromosome in lymphocytes of female carriers as
well as reports demonstrating a random pattern of X chromo-
some inactivation in obligate carriers have appeared in the litera-
ture (1, 25, 26). These conflicting reports may be due to the
heterogeneity of the hyper IgM syndrome. The molecular char-
acterization of HIGM1, demonstrating that mutations in the T
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Figure 4. Flow cytometry analysis of activated CD4'
with anti-CD3 and CD40-Ig in a two-color immunofli
Displayed is the staining with CD40-Ig of the populatic
cell surface protein gp39 are the basis for the
has allowed the reexamination of the pattern of
inactivation in the lymphocytes of female carri
Using nucleic acid sequencing, PCR analysis, ano
ing studies we have obtained detailed family pe
affected families. This has allowed us to identi
female carriers of the defective gene. Messenger
gp39 was isolated from the in vitro activated I
female carriers from two different families and
cDNA. Multiple independent cDNA clones enco
each carrier were sequenced. These experiment
the pattern of X chromosome inactivation in tl
these female carriers was quite heterogeneous.
ined the levels of functional gp39 protein ex
surface of the in vitro activated T cells obtain
carriers from these two families and found th
functional gp39 correlated very well with the n
clones encoding wild-type gp39. A third fami
fected males was also analyzed. DNA sequencih
the mutation responsible for the defect in this fa
amino acid deletion in the extracellular domaii
large deletion allowed the development of a PC
for the rapid detection of the mutation in other f
Although this method does not allow a deter
degree of skewing of the X chromosome inactiv
the facile identification of female carriers. An
members studied, two female carriers were iden
tion of the T cells of these female carriers sA
express the normal and the mutated gene at appr
levels. These observations support the previou
suggest that in lymphocytes of female carriers tt
ential selection for T cells in which the normal
is active.
Because of the random inactivation of the
carrying the defect, this could not be used t
carriers as has been suggested for detection of e
XSCID and Wiskott-Aldrich syndrome (27-29
K.H. tive, we wished to determine if a simple antibody based immu-
32% nofluorescence assay could be developed for the detection offemale carriers of HIGM1. The heterogeneity of obligate carri-
ers in terms of the proportion of cells expressing the defective
gp39 indicated that examining the binding of CD40-Ig to acti-
A ~ vated PBMCs may not be sufficient to distinguish carriers from
noncarriers. To increase the sensitivity of the assay in an effort
to detect low numbers of cells that express defective gp39, we
isolated CD4' T cells, activated the cells in vitro and performed
C.C. two color immunofluorescence assays using CD40-Ig and
50%/o monoclonal antibodies against either the T cell marker CD3
or the lymphocyte activation marker CD69. This manipulation
identified a subpopulation of T cells, 90% of which express
gp39 in unaffected individuals. The female carriers Lyonized
towards expression of the defective gp39 have a substantial
population of CD69+/gp39- and CD3+/gp39- cells when com-
2 3 4 pared to the normal controls. However, there is no advantage
gained using this method in the ability to detect carriers in
which the wild type gp39 is predominant, as demonstrated by
the staining of CD4' cells obtained from the carrier J.S.
T cells stained The pattern of X chromosome inactivation and the clinical
uorescence study. history of female carriers of X-linked immunodeficiencies may
)n that was CD33. provide important information on the pathobiology of the dis-
ease and on the role of the gene product in the immune response.
Extreme Lyonization may result in the phenotypic expression
HIGM1 defect, of an X-linked disease in a female carrier as evidenced by cases
X chromosome of hemophilia A, Wiskott-Aldrich syndrome and Duchenne
iers of HIGM1. muscular dystrophy observed in females (30-33). In the case
d receptor bind- of HIGM 1, female carriers are asymptomatic and serum levels
digrees of three of immunoglobulins are within normal ranges, despite low num-
ify a number of bers of T cells expressing gp39 (< 30%). This suggests symp-
RNA encoding toms of X-HIM are prevented by the presence of a small per-
PBMC of three centage of T cells able to express functional gp39. The role of
used to prepare the CD40/gp39 interaction in antibody production suggests this
ding gp39 from may be a potential therapeutic target in the treatment of anti-
ts indicated that body-mediated autoimmunity. The lack of a phenotypic effect
he T cells from of severely reduced levels of gp39 in female carriers of HIGM 1
We also exam- suggests that a very high level of inhibition of the gp39/CD40
cpressed on the interaction would be necessary for effectiveness. Preliminary
ed from female in vivo studies have shown that onset of collagen induced arthri-
iat the levels of tis could be prevented in a murine model by the administration
umber of cDNA of anti-gp39 monoclonal antibody (34). These results suggest
ly with five af- that in the pathological condition, sufficient inhibition of the
ng revealed that interaction can be achieved and that inhibitors of the gp39/
imily was a 21 - CD40 receptor ligand pair have therapeutic potential in the
n of gp39. This treatment of autoimmune diseases.
R based method The pattern of X chromosome inactivation in female carriers
amily members. of X-linked diseases may provide information on the role the
mination of the affected gene plays in lymphocyte development. For example,
ation, it allowed the X chromosome carrying the defective gene is inactivated in
nong the family B cells of carriers of XLA (35), and B and T cells of carriers
itified. Examina- of X-linked SCID (29). This unilateral pattern of X chromosome
iowed that they inactivation reflects the disadvantages conferred on the cells
-oximately equal that express the defective gene during differentiation and prolif-
is reports which eration. Indirect evidence has implicated the gp39/CD40 inter-
iere is no prefer- action in T cell development. CD40 is expressed by thymic
X chromosome epithelial cells and anti-CD40 mAb in the presence of INF--y
or IL-l triggers the release of GM-CSF (12). However, in vitro
X chromosome activated thymocytes did not bind to CD40-Ig suggesting that
lo detect female they lack expression of gp39 (C. P. Edwards and C. B. Wilson,
carriers of XLA, personal communication). Although additional experiments are
i). As an altema- needed to elucidate the role, if any, of gp39 in T cell develop-
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ment, the lack of preferential inactivation of the mutated X
chromosome in the T cells of female carriers of HIGM1 sug-
gests that expression of gp39 during T cell ontogeny is not
critical for T cell development.
The identification of the defect in the X-HIM syndrome as
a defect in the gene encoding gp39 allows a comparison of
known roles of the receptor ligand pair with the clinical manifes-
tations of the disease. The importance of the CD40 ligand/
receptor pair in the interaction between B and T cells has been
suggested by in vitro experiments. Through the use of mAb,
stimulation of the CD40 receptor was found to induce B cell
proliferation and isotype switching in the presence of an appro-
priate costimulus. The absence of isotype switching in the X-
HIM patients confirms this role of the gp39/CD40 ligand recep-
tor pair. The recent identification of CD40 on the surface of
monocytes, and the resulting cytokine induction when the recep-
tor is engaged, demonstrates another role for the ligand pair
(10). The increased frequency of P. carinii infection and malig-
nancies, generally considered to be a consequence of a T cell
defect, may be a result of the lack of monocyte-derived T cell
stimulation. The neutropenia observed in some X-HIM patients
may also be caused indirectly, by the absence of cytokines
normally produced in response to CD40 stimulation, as there is
no known direct role of gp39 in the ontogeny or maintenance
of this cell population. A recent report has demonstrated that
B cell apoptosis upon antigen stimulation is prevented by CD40
costimulation, suggesting a role for CD40 during the elimination
of self reactive B cells (36). In the absence of CD40 stimulation,
all B cells might be expected to be eliminated. As the HIM
patients have normal numbers of functionally active B cells, a
mechanism other than CD40/gp39 interaction must be available
for the prevention of apoptosis.
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